IDEAYA starts phase 1/2 trial of IDE892 for pancreatic, lung cancers

June 15, 2026 6:00 AM

IDEAYA Biosciences Inc. (NASDAQ: IDYA) has enrolled its first patient in a Phase 1 clinical trial evaluating IDE892, an inhibitor ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found